US FDA grants fast track designation to Rznomics’ gene therapy-based cancer drug candidate, RZ-001: Seongnam, South Korea Wednesday, February 19, 2025, 16:00 Hrs [IST] Rznomics, ...
The US FDA has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular carcinoma (HCC).
Rznomics announced on the 14th that its anticancer drug, RZ-001, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC ...